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ABSTRACT 
This thesis is part of research efforts with the intent of applying chemical stability and 
drug degradation kinetics knowledge to lipid-based systems, as amphotericin B (AmB) 
usually requires a lipid-based nanotechnological delivery system to overcome its 
biopharmaceutical issues. The aim of this thesis was to determine the instability 
pathway and degradation kinetics of AmB in oil solutions, since stability of drug in 
delivery systems are chemically complex to be investigated due to their multi-phased 
aspect. This thesis was driven on the hypothesis that AmB´s toxicity might be 
associated to the drug degradation instead of what is reported by the literature, which 
is mainly related to the drug´s aggregation state. The experimental research herein was 
conducted in order to investigate the chemical instability pathways and kinetics of 
AmB in oils, aiming to generate knowledge that can be useful on a larger context 
involving microemulsions currently studied by our research group. For this purpose, 
reaction mixtures containing AmB were prepared using different solvents and co-
solutes. Samples were stored under different conditions of temperature and light 
exposure. AmB aggregation state in the reaction mixtures was investigated by UV-Vis 
spectroscopy. The degradation pathway of AmB in oil was investigated. The results 
revealed that the use of hydrogen donator antioxidants decreased the degradation of 
AmB under thermal stress. Also, the AmB degradation under dark conditions was not 
linearly temperature dependent. Additionally, the use of radical initiator greatly 
increased the degradation of AmB in methanol. Based on the obtained results, 
adsorption and aggregation did not appear to play an important role in the AmB 
degradation in oil. Under dark conditions, the most likely pathway for AmB 
degradation in oil was autoxidation, whereas under light exposure, the most likely 
degradation pathway was light catalyzed oxidation. Empirical degradation schemes 
 
 
 
   
7
were drawn and differential equations were developed to explain the AmB loss 
process. A kinetic model was successfully used to describe the AmB loss in different 
solvents under dark environment. The model proved that AmB undergoes a complex 
degradation pathway, once a simple autocatalytic model could not describe its loss. In 
fact, a reversible loss probably related to hydrolysis might be involved, as 
demonstrated by the scheme and the kinetic model. A second model successfully 
described the AmB loss under light exposure. AmB loss in this condition showed to 
be of pseudo-first order. Due to the complex degradation pathway, the kinetics of the 
different processes leading to the AmB degradation could not be distinguished. The 
information generated by this research will help to predict AmB instability in 
microemulsion systems, once the data of AmB degradation in aqueous phase and 
surfactants will be associated. Additionally, further efforts on trying to generate and 
isolate the degradants here suggested can help on the investigation of the toxicity 
related to degradation products.  
Keywords: Amphotericin B; Microemulsions; Drug Degradation; Oxidation; 
Chemical Kinetics. 
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RESUMO 
Esta tese foi gerada como parte dos esforços em gerar conhecimentos de estudos de 
estabilidade química e cinética de degradação que possam ser aplicados a 
microemulsões contendo Anfotericina B (AmB). O objetivo desta tese foi determinar 
as vias de degradação da AmB em óleo, visto que microemulsões são multifásicas e 
de composição complexa. Esta tese mostra esforços experimentais em determinar as 
vias de degradação da AmB em óleo, assim como determinar o esquema de degradação 
e o modelo matemático que reflita o comportamento de degradação desta molécula em 
solução lipídica. Diferentes soluções contendo AmB em óleo foram preparadas e 
armazenadas em diferentes condições de temperatura e luz, assim como presença e 
ausência de co-solutos. Estudos analíticos foram feitos por Espectrofotometria UV-
Vis e por método validado em Cromatografia Líquida de Alta Pressão. Foi possível 
observar que o uso de antioxidantes doadores de hidrogênio no meio reacional 
aumentou a estabilidade de AmB sob estresse térmico ao longo do tempo. Entretanto, 
a cinética de degradação da AmB em triglicerídeo de cadeia média não foi linearmente 
dependente da temperatura. A adição de um iniciador radicalar aumentou a degradação 
da AmB em metanol. Adicionalmente, baseado em estudos de adsorção e agregação, 
foi possível observar que estes fenômenos não estão diretamente relacionados a 
degradação da AmB em óleo. Em armazenamento protegido da luz, a via de 
degradação mais provável por ser responsável pela perda de AmB do meio reacional 
é a auto-oxidação. Enquanto sob luz visível e UV, a oxidação catalisada pela luz é 
predominante. Modelos cinéticos foram construídos baseados nestas evidências 
experimentais. O modelo complexo para condições protegidas de luz mostrou que a 
AmB sofre não somente auto-oxidação, mas perda reversível, que pode estar 
relacionada à hidrólise por água residual. O modelo para degradação sob exposição à 
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luz foi de pseudo-primeira ordem. Os modelos teóricos representaram os dados 
experimentais adequadamente e as constantes cinéticas foram estimadas. Entretanto, 
devido a degradação ocorrer por vias de degradação múltiplas e concomitantes, os 
parâmetros cinéticos de cada processo envolvido não foram estimados. As 
informações geradas por esta tese ajudarão a estimar adequadamente a cinética de 
degradação em sistemas de liberação complexos quando associados aos dados 
cinéticos nas demais fases em que o fármaco esteja presente. Além disto, este estudo 
sugeriu possíveis produtos oriundos da oxidação da AmB. Portanto, estudos de 
identificação e síntese devem ser realizados a fim de investigar a relação da toxicidade 
da AmB e seus produtos de degradação.  
 
Palavras-chave: Anfotericina B; Microemulsões; Estabilidade química; Cinética de 
degradação; Oxidação. 
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CHAPTER 1 
 
Introduction, Peer collaborated efforts and Objectives 
 
1.1. Introduction  
 
Amphotericin B (AmB) is an antifungal and antiprotozoal drug that was 
originally isolated from Streptomyces nodosus. It is a macrolide composed of a 
macrocyclic lactone ring containing 37 carbons atoms (Figure 1).  
 
Figure 1 – Structure of amphotericin B showing the numbering of carbon 
atoms in the molecule 
 
A heptaene from carbon 20 to carbon 33 provides a non-polar characteristic to 
the molecule (Driver et al., 1990), whereas the presence of seven hydroxyl groups and 
one carboxyl group provides some polarity. As a result, this molecule is amphiphilic 
(Andreoli, 1974). AmB contains a carboxyl group (pKa 5.5) and a primary amine group 
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(pKa 10), the later attached to a mycosamine ring (3-Amino-3,6-dideoxy-β-D-
mannopyranose) which is connected to the main macrocyclic chain by an o-glycoside 
linkage at carbon 19. The anionic carboxylic acid and cationic protonated amino group 
result in a zwitterion with amphoteric characteristic (Chéron et al., 1988; Hellgren et 
al., 1995).  
Clinically, AmB is used for the treatment of invasive fungal infections, and it 
has a broad spectrum of action, including strains of Candida spp. and Aspergillus spp., 
and other filamentous fungi (Klepser, 2011). However, high nephrotoxicity has limited 
its use to second-line treatment when first course with azoles or echinocandins 
(regarding patients’ conditions and specific infection) fails to eliminate the infections 
(Fanos e Cataldi, 2000; Walsh et al., 2008; Pappas et al., 2009). Additionally, AmB is 
used to treat visceral leishmaniasis, an infectious disease caused by protozoan parasites 
of the genus Leishmania. Leishmaniasis is a public health issue in many tropical, 
subtropical and Mediterranean countries as well as rural southern United States. 
Untreated infections can be fatal. The first choices of treatment for the diseases are 
antimonial agents. However, in many countries, AmB is considered first choice of 
treatment due to Leishmania resistance to antimonial drugs (Chattopadhyay e 
Jafurulla, 2011; Mosimann et al., 2018).  
Although AmB is considered a useful drug for systemic fungal infections and 
visceral leishmaniasis (Chattopadhyay e Jafurulla, 2011), severe toxicity usually 
attributed only to AmB aggregated forms interaction to human cells cholesterol 
molecules hinders its clinical use. The infusion of traditional formulations 
(amphotericin B deoxycholate) can cause shaking, fever, vomiting, tachypnea and may 
require co-administration of antipyretics, antihistamines, antiemetics and 
hydrocortisone to reduce the side effects during treatment (Klepser, 2011). On the 
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other hand, administration of lipid formulations of AmB are associated to reduced 
toxicity and enables the use of this drug for prophylactic use (Hann e Prentice, 2001; 
Mosimann et al., 2018).  
Lipid-based AmB delivery systems are currently being developed to reduce 
dosage, increase potency, reduce cost and enhance bioavailability and 
pharmacokinetics profiles (Hann e Prentice, 2001). Recent in vitro and in vivo studies 
have focused on the use of AmB microemulsions to treat fungal infections and 
leishmaniasis (Darole et al., 2008; Damasceno et al., 2012; Silva et al., 2013; Morais 
et al., 2016). Microemulsions are colloidal dispersions of two immiscible phases 
stabilized by a surfactant interfacial film, which are characterized as isotropic, clear 
and thermodynamically stable (Mouri et al., 2014). Microemulsion droplets range in 
size from 10 to 100 nm, and therefore, can be used for parenteral administration (Date 
e Nagarsenker, 2008).  
Regardless of the delivery system, stability studies are required to optimize 
storage conditions and shelf-life. Drug product stability means the maintenance of all 
product performance attributions during manufacture, distribution, storage and 
product use. Product performance attributes include chemical integrity, physical 
integrity, therapeutic effectiveness, safety, sterility, utility and sensory acceptability. 
Chemical stability relates to maintaining chemical potency and purity, and limiting the 
generation of degradation products (covalent transformations). Physical stability 
relates to organoleptic characteristics, phase changes, non-covalent changes such as 
aggregation, polymorphism, coalescence and droplet size growth. Last, therapeutic 
and safety stabilities relates to the maintenance of unchanged therapeutic effects and 
prevention of toxicity increase, respectively (Ansel et al., 2005). Furthermore, the 
knowledge of drug degradation kinetics and products of degradation related to the 
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specific lipid medium can provide information regarding optimum manufacture 
conditions, excipient-drug stability for compounding optimization and toxicity. 
Despite extensive research on trying to improve stability of delivery systems, 
whether is by adding conservatives, or by freeze-drying in order to remove water from 
systems; and regardless the extensive efforts on AmB delivery systems research, very 
few studies have been reported on its chemical stability. In particular, the identity and 
toxicological safety of AmB degradation products and the kinetics of their formation 
in various environmental conditions and drug delivery systems has not been reported.  
Studies have demonstrated that AmB toxicity is reduced in lipid-based delivery 
systems (Brime et al., 2003; Damasceno et al., 2012; Wasko et al., 2012; Mosimann 
et al., 2018). However, it is unclear whether reduced toxicity is due to reduced dimer 
and AmB-aggregate concentrations or changes in the pattern and rate of degradation 
product formation. 
Although being an old molecule and having widespread use for leishmaniasis 
and fungal infections in lipid-based systems (such as the liposomal AmBisome®, and 
the widely studied emulsioned systems) the limited data on AmB degradation only 
concerns aqueous media and organic solvents (Hamilton-Miller, 1973; Beggs, 1978; 
Lamy-Freund et al., 1985; Hung et al., 1988). Thus, not only is necessary to investigate 
the influence of the degradation products of AmB on its toxicity, but how this drug 
behaves in lipid-based media and which degradation pathway is the main responsible 
for its degradation. This way, it would be possible to control or prevent drug 
degradation in those formulations, once different processes may be predominant in 
different type of media.  
In this context, High Performance Liquid Chromatography (HPLC) is a useful 
technique for the separation and quantification of low degradant concentration in 
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complex mixtures. However, in order to obtain reliable results, method validation must 
be performed (Kazakevich e Lobrutto, 2007). Validation is a standardized process for 
reducing error to ensure accurate and precise measurements with adequate sensitivity, 
selectivity and linearity above the limits of detection and quantification (Ich, 1996; 
Fda, 2001; Skoog et al., 2007). 
This thesis will show current efforts in evaluating the chemical stability of 
amphotericin B in lipid-based media, since besides the work being done on 
development, characterization and in vitro and in vivo studies regarding lipid-based 
systems containing amphotericin B, little is known regarding its chemical stability in 
different media and how this stability might play a role on aggregation, 
pharmacological activity and toxicity.  
 
 
1.2. Peer Collaborated Efforts   
 
The Graduate Program in Pharmaceutical Nanotechnology is a Ph.D. program 
composed of researchers from several Brazilian Universities, with expertise in 
production, characterization and evaluation of nanotechnological delivery systems for 
diverse routes. Part of the work herein presented was done in collaboration with Master 
and Doctorate students from Brazil and France, specially the work related to 
nanotechnology. 
In order to increase the knowledge of drug stability applied to microemulsions, 
the experimental research of this thesis was developed at The University of Iowa – 
College of Pharmacy – Division of Pharmaceutics and Translational Therapeutics 
under the guidance of Prof. Lee. E. Kirsch, Ph.D., who has generously joined 
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collaborative efforts to Prof. Socrates Egito, Ph.D. (Federal University of Rio Grande 
do Norte (UFRN), member of the Graduate Program in Pharmaceutical 
Nanotechnology to advise me on the development of this project. 
 
 
 
 
 
1.3. Thesis Structure 
 
As a doctorate student from this program, my initial efforts regarding research 
were towards development and characterization of delivery systems with amphotericin 
B and also natural oils in the field of nanotechnology. However, as a need to provide 
valuable information regarding amphotericin B stability, my research switched in the 
very beginning of the doctorate studies mainly to the stability studies of this drug 
aiming to provide valuable and needed information to be applied in future studies 
involving amphotericin B incorporated in lipid-based systems. Based on this context, 
this thesis was organized in the following way: 
Chapter I provides literature background, peer collaborative efforts, a general 
explanation of the Thesis structure and the Objectives of the work.  
Chapter II presents the efforts to develop and validate an analytical method to 
quantify amphotericin B in oils, as well as efforts to determine the predominant 
pathway of degradation of this drug in different lipid-based reaction mixtures.  
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In Chapter III, the quantification of AmB degradation kinetics are presented 
using the suggested empirical model for substrate loss under different environmental 
conditions. 
Furthermore, in the Appendix, additional collaboration work regarding 
microemulsions containing amphotericin B, analytical methods of analysis for 
quantifying and characterizing natural oils, and papers regarding the development of 
nanostructured delivery systems based on natural products are shown. Although 
covered by the scope of the Graduate Program in Pharmaceutical Nanotechnology, 
these papers are not the focus of this thesis. However, they are shown as a parallel 
project I was involved as a student on the area of expertise of this program and 
contributed to my education towards obtaining the degree of Doctor in Pharmaceutical 
Nanotechnology.  
 
1.4. Objectives 
General Objective 
The long-term research goals involved in this research were to determine the 
chemical instability pathways and kinetics of AmB in complex drug delivery systems 
currently studied by our research group, mainly emulsions and microemulsions, and 
to determine if the generation of degradation products was associated to the drug 
toxicity. However, due to the complex nature of these systems and the different 
degradation behavior a drug may have in different media, the objective of this thesis 
was to determine the instability pathway and degradation kinetics of AmB in oil 
solutions.  
Specific objectives 
The specific objectives pursued in this work, as explored along the next chapters, were: 
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Specific Aim 1: Quantify AmB from oil solutions.  
An extraction method was developed to recover AmB from oil for posterior 
quantitation. A HPLC/UV-Vis method able to accurately measure low concentrations 
of AmB was developed and validated.  
Specific Aim 2: Determine if adsorption and aggregation play a role on AmB loss 
and if AmB undergo oxidation  
Adsorption testing was performed to determine if this process accounts for 
AmB loss observed by analytic methods. In addition, aggregation of AmB was 
assessed along stress testing to determine if different aggregation forms of this drug 
play a role on AmB degradation kinetics in lipid media. 
Stress testing under oxidative conditions were performed with AmB in oils 
solutions in order to determine if the drug degrades under different oxidative pathways.  
Specific Aim 3: Determine degradation rates and predict degradation scheme and 
model for AmB loss 
A degradation scheme for AmB loss was suggested according to the conditions 
tested. An empirical model was developed, and kinetic parameters were determined. 
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CHAPTER 2   
 
 
This chapter contains a research paper manuscript about the validation of a 
HPLC method for quantifying AmB extracted from oil samples, AmB solubility 
determination in medium chain triglycerides and the role of media on the degradation 
of AmB, as well as an attempt to determine the degradation pathway of AmB in oils 
and reaction mixtures. 
The manuscript focusses on determining the primary pathway of AmB 
degradation based on the hypothesis that autoxidation is the main pathway in organic 
solvents. However, the manuscript presents efforts to investigate alternate pathways 
that could be responsible for substrate loss detectable by the developed analytical 
method. As well as shows different investigations into the oxidation theory, such as 
using reaction mixtures containing antioxidants with different mechanisms of action, 
investigating the influence of the type of solvent and presence/absence of light. 
We intend to submit this research article to the Journal of Pharmaceutical and 
Biomedical Analysis upon completion and editing of this manuscript. 
 
 
 
 
 
 
 
 
 
 
   
29
Studies on amphotericin B instability in lipid-based media, Part I: Identification 1 
of degradation pathways as function of mixture conditions 2 
 3 
Éverton do Nascimento Alencar1,2, Phawanan Sawangchan2, Lee E. Kirsch2 and 4 
Eryvaldo Sócrates Tabosa do Egito1. 5 
 6 
1- Universidade Federal do Rio Grande do Norte, Centro de Ciências da Saúde, 7 
Programa de Pós-Graduação em Nanotecnologia Farmacêutica, Laboratório 8 
de Sistemas Dispersos, Rua Gustavo Cordeiro de Farias, SN. Petrópolis. 9 
CEP: 59012-570 Natal/RN- Brazil.  10 
2- The University of Iowa, College of Pharmacy, Division of Pharmaceutics and 11 
Translational Therapeutics, 115 South Grand Avenue, Iowa City, IA 52242, 12 
U.S.A. 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
Corresponding author: 21 
Eryvaldo Sócrates Tabosa do Egito, Ph.D. 22 
Rua General Gustavo de Farias 23 
59012-570 Natal/RN - Brazil 24 
Fax: +55 84 3342-9808/ +55 84 3342-9817. E-mail: socratesegito@gmail.com  25 
 
 
 
   
30
ABSTRACT 26 
 27 
The aim of this work was to determine the predominant degradation pathways of 28 
amphotericin B (AmB) as a function of different organic reaction mixtures in oil and 29 
storage conditions in lipid-based solutions. For this purpose, UV-Vis Spectroscopy 30 
and HPLC analytical methods were developed and HPLC method validated in order 31 
to accurately quantify AmB. In this study, the method described proved to be 32 
reproducible and accurate with linearity (R2 = 0.996) from 3.2 to 52.0 nM using a UV 33 
detector. LOD and LOQ were 1.33 and 4.45 nM, respectively. AmB was successfully 34 
extracted from medium-chain triglyceride based oil prior HPLC analysis and AmB 35 
solubility in medium-chain triglyceride was determined to be approximately 1.0 µM. 36 
Different reaction mixtures were done using different solvents, antioxidants and 37 
radical initiator. Samples were stored under different conditions of temperature and 38 
light exposure. AmB aggregation state in reaction mixtures was investigated by UV-39 
Vis spectroscopy. The degradation pathway of AmB in oil was investigated. Use of 40 
hydrogen donator antioxidants decreased the degradation of AmB under thermal 41 
stress. AmB degradation under dark conditions was not temperature dependent. Use 42 
of radical initiator increased the degradation of AmB in methanol greatly. Based on 43 
the obtained results, adsorption and aggregation did not appear to play a role in AmB 44 
degradation in oil. The degradation pathways of AmB were related to oxidation 45 
processes and were found to be light-dependent. Under dark conditions, the most likely 46 
pathway for AmB degradation was autoxidation. Whereas under light exposure, the 47 
most likely degradation pathway was light catalyzed oxidation.    48 
Keywords: Amphotericin B; Autoxidation; Drug Degradation;  49 
 50 
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1. INTRODUCTION 51 
 52 
Amphotericin B (AmB) is an antibiotic synthesized by Actinomycetes 53 
microorganisms (mainly Streptomyces spp.) that was first introduced as an antifungal 54 
agent [1]. AmB contains a carboxyl group (pKa 5.5) and a primary amine group (pKa 55 
10), the later attached to a mycosamine ring (3-Amino-3,6-dideoxy-β-D-56 
mannopyranose) which is connected to the main macrocyclic chain by an o-glycoside 57 
linkage at carbon 19. The anionic carboxylic acid and cationic protonated amino group 58 
result in a zwitterion with amphoteric characteristic [2, 3]. Additionally, the presence 59 
of seven hydroxyl groups on the aliphatic chain and a heptaene on the macrocycle 60 
provide an amphiphilic characteristic to the molecule [4] (Figure 1).  61 
 62 
FIGURE 1 63 
 64 
To this date, no investigative studies have been performed in order to determine 65 
the degradation pathway of AmB in oil. However, studies have been performed in 66 
aqueous media, as well as in organic solvents. Hung and Collaborators [5], performed 67 
a study using a factorial design to determine which variables would influence on AmB 68 
degradation. The study involved different conditions as dependent variables, including 69 
temperature, light, ionic strength, oxygen, surfactant concentration and pH. Although 70 
none of the conditions involved oil as solvent, the study suggested that AmB is more 71 
stable in darkness, in the absence of oxygen and at low temperature, no further 72 
investigations or discussion regarding degradation pathway was done. 73 
Recent study from our research group showed that in aqueous media, at 74 
extreme conditions, such as high and low pH, hydrolysis is the most predominant 75 
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degradation pathway. On the other hand, oxidation plays a bigger role on the 76 
degradation of this drug at neutral pH (Unpublished data), as also suggested by Lamy-77 
Freund and collaborators [6], which performed studies in a mixture of aqueous and 78 
organic media to investigate the generation of free radicals by Electron Spin 79 
Resonance (ESR). The authors also monitored the oxygen consumption throughout the 80 
experiment. The study supported the hypothesis of degradation by autoxidation at this 81 
reaction media.  82 
Furthermore, the aggregational state of AmB, which has been widely 83 
associated to this drug´s toxicity [7], affects directly the total loss of AmB substrate in 84 
aqueous media, as mentioned by Lamy-Freund and collaborators [8]. The study 85 
showed that aggregated form in water/DMSO mixture had slower degradation rates 86 
than AmB in its monomeric state, evidence of the influence of aggregation in the 87 
kinetics of degradation. However, the study did not quantify AmB directly, instead 88 
they only investigated degradation by determining free radical formation.  89 
As observed in the literature, there is a lack of information regarding 90 
amphotericin B chemical stability in lipid-based media. The studies above performed 91 
in aqueous media did not discussed possible other oxidation reactions other than 92 
autoxidation to be involved in the degradation of AmB. Furthermore, it is still unclear 93 
if aggregation plays a role on different AmB degradation pathways in lipid-based 94 
media. For this reason, a great amount of information is still needed before accurately 95 
inferring the relation between amphotericin B instability and its pharmacological and 96 
toxicological effects In lipid media. Thus, the aim of this work was to determine the 97 
predominant degradation pathway of AmB as a function of different reaction mixtures 98 
and storage conditions in lipid-based solutions. For this purpose, analytical methods 99 
were developed and validated in order to accurately quantify AmB. 100 
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2. MATERIALS AND METHODS 101 
2.1  Chemicals 102 
 Amphotericin B (Product number: A4888, Purity ≥ 80 % (HPLC)), 103 
carbamazepine, methanol CHROMASOLV® for HPLC, butylated hydroxytoluene 104 
(BHT), benzylic alcohol, chloroform, butanol, peanut oil and azobisisobutyronitrile 105 
(AIBN) were acquired from Sigma Aldrich (St. Louis, MO, USA). Soybean oil was 106 
obtained from Spectrum Chemical (New Brunswick, NJ, USA). Acetonitrile HPLC 107 
grade, dimethyl sulfoxide (DMSO) and ethylenediaminetetraacetic acid, disodium salt 108 
(EDTA) were purchased from Fisher Scientific (Hampton, PA, USA). Propyl gallate 109 
and α-tocopherol were obtained from Acros (NJ, USA). Miglyol® 812 was a gift from 110 
Cremer Oleo GambH & Co. KG (Hamburg, Germany). HPLC grade deionized water 111 
(Nanopure Infinity - Barnstead thermolyne, MN, USA) was used throughout the 112 
experiments. All other chemicals were ACS reagent grade.  113 
 114 
2.2 Instrumentation 115 
 HPLC analyses were carried out using a Waters Alliance 2695 separation 116 
module (Waters Corporation, MA, USA) coupled to a Waters 2487 Dual λ Absorbance 117 
detector set at 406 nm for AmB and at 284 nm for Carbamazepine. The column 118 
consisted in a Hypersil BDS C18 of 250 mm x 4.6 mm (Thermo Scientific, MA, USA). 119 
The mobile phase consisted of 5 mM Na2EDTA aqueous solution and acetonitrile 120 
(65:35, v/v). Flow rate was 0.5 mL/min. Temperature of the sample holder and the 121 
column were set at 4 °C and 25 °C, respectively. HPLC method was adapted from 122 
previous studies [Unpublished Article]. 123 
UV absorbance Scans were performed using a Hewlett Packard 8453 diode-124 
array UV-Visible spectrophotometer. The method was adapted from previous studies 125 
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from our research group [9]. A quartz cuvette with a path length of 1 cm was used and 126 
the solutions were scanned in the range of 250 to 500 nm. Data were analyzed using 127 
UV-Visible ChemStation software. A.05.04. 128 
  129 
2.3 HPLC method validation 130 
 131 
The validation of the HPLC method followed the U S Food and Drug 132 
Administration guidance for Industry with adaptations [10].   133 
2.3.1 Calibration Curve 134 
 A stock solution was prepared by weighing 20 mg of AmB and transferring 135 
the drug to a 100 mL volumetric flask that had its final volume completed with 136 
methanol. The stock solution was 174.0 µM based on 80.00 % purity of bulk drug and 137 
it was used to prepare calibration standards by series dilution. The solutions had 138 
concentrations of 3.2, 6.5, 13.0, 26.0 and 52.0 nM in methanol:DMSO (3:2, v/v). AmB 139 
solutions were kept in vials protected from light during the experiment.  140 
2.3.2 System suitability 141 
 The suitability of the system was assessed by analyses of 6 injections of AmB 142 
at 13.0 nM. The criterion of acceptance was ± 2 % for the coefficient of variation 143 
percent (% CV) for retention times and ± 10% for both the peak area and peak height. 144 
2.3.3 Linearity 145 
 The linearity was verified by investigating if the solutions concentration 146 
range is where analyte response is linearly proportional to concentration. The AmB 147 
peak area was considered for plotting the linearity graph and the analysis was based 148 
on the least square regression method. Linearity curves were performed in three 149 
different days.  150 
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2.3.4 Precision/Accuracy  151 
The precision studies were performed by intermediate precision (between-152 
day) and repeatability (within-day). 3.2, 13.0 and 52.0 nM solutions were used in both 153 
tests. Repeatability was performed by injecting triplicate samples of the studied 154 
solutions. Intermediate precision was performed by injecting the three samples in four 155 
consecutive days. Results were expressed as the average ± standard deviation and the 156 
coefficient of variance was used to assess the precision. Accuracy was determined by 157 
calculating the percent nominal mean of six repetitions for concentrations 3.2, 13.0 158 
and 52.0 nM. 159 
2.3.5 Limits of detection and quantification: 160 
 Limit of detection (LOD) and limit of quantification (LOQ) were obtained 161 
based on calibration curve data (slope and standard deviation) using AmB solutions in 162 
methanol:DMSO (3:2, v/v), as described in previous section.  163 
2.4 Extraction of AmB from oil solution  164 
A liquid/liquid separation method was adapted from the literature to extract 165 
the AmB from oil (Miglyol® 812) solutions for HPLC analysis [11]. A 1.0 mL aliquot 166 
of AmB oil solution was mixed with 4.0 mL of DMSO. The mixture was stirred on 167 
vortex for 2 minutes and allowed to separate for 2 hours at 25 °C while protected from 168 
light. After separation, 2.0 mL from the bottom phase were removed from the tube and 169 
transferred to a vial containing 3.0 mL of methanol. The resultant solution was mixed 170 
and analyzed by HPLC. The calibration standards were prepared in a solvent 171 
composed of 3 parts of methanol and 2 parts of DMSO as the resultant solution from 172 
extraction.  173 
Extraction yield was calculated comparing the extracted sample to a control 174 
AmB solution in DMSO, which was prepared at the same theoretical AmB 175 
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concentration of the extracted sample at the analytical step. This solution was analyzed 176 
by HPLC. Extraction time requirement was determined measuring AmB recovery 177 
periodically over 54 hours of extraction. Samples were stored at 25 °C and kept 178 
protected from light during the extraction. The experiment was conducted in duplicate 179 
and the samples were analyzed by HPLC three times. 180 
2.5 Determination of solubility of AmB in medium-chain triglyceride  181 
The solubility of amphotericin B in medium-chain triglyceride (Miglyol® 182 
812) was determined. A mixture containing an excess of AmB in oil (1mg in 25 mL) 183 
was placed in microcentrifuge tubes and kept under magnetic stirring for 52 hours at 184 
25 °C. Samples were prepared in duplicate. Each sample was centrifuged at 8000g for 185 
45 min at 25 °C. The supernatants were collected, extracted and analyzed by HPLC in 186 
triplicate. 187 
2.6 Reaction mixtures preparation 188 
A series of reaction mixtures containing AmB at 0.8 µg/mL (0.86 µM) were 189 
prepared by diluting a stock solution of AmB 160 µg/mL (174.0 µM) in methanol with 190 
Miglyol® 812, peanut oil and soybean oil. Reaction mixtures involved the use of co-191 
solutes, such as the radical initiator AIBN (0.7mg/mL) and the antioxidants propyl 192 
gallate (5.0 mg/mL), α-tocopherol (1.0 mg/mL) and BHT (2.5 mg/mL). Besides using 193 
the oils mentioned above as solvents, methanol was used in order to overcome 194 
drawbacks related to the use of oil, such as solute solubility in oil, need for extraction 195 
of compounds for posterior HPLC analysis or its spectroscopic properties. The studies 196 
in methanol involved the same co-solutes; However, the influence of antioxidant 197 
concentration was evaluated by increasing the concentration of BHT from 10 to 150 198 
mg/mL. In addition, AIBN was added to the stock solution of AmB in methanol (160 199 
µg/mL) in order to initiate AmB degradation and observe possible formation of 200 
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degradants detectable by the HPLC method. AmB 0.8 µg/mL reaction mixtures at 201 
ambient temperature in benzylic alcohol, butanol, chloroform, methanol, Miglyol® 812 202 
and octanol were used in the study of the effect of AmB aggregation state.  203 
Furthermore, carbamazepine was used as a model drug that is known to 204 
degrade by oxidation and it has its degradation scheme elucidated [12]. Reaction 205 
mixtures of carbamazepine 1 µg/mL and AIBN 0.7mg/mL in the solvents mentioned 206 
previously were made in order to investigate the effectiveness of this radical initiator 207 
at the work concentration.  208 
All reaction mixtures were submitted to different storage temperatures 209 
(ambient temperature, 30, 40, 50, 60, 70 and 80 °C) depending upon the study. 210 
Reaction mixtures were placed in transparent glass vials, always protected from light, 211 
with the exception to the samples submitted to photodegradation study.  212 
The study of adsorption involved only the reaction mixture of AmB 0.8 213 
µg/mL in Miglyol® 812 stored at 60 ºC in scintillation vials containing different 214 
amount of glass beads to analyze if drug loss changed with increase of surface area. 215 
The surface areas in contact with the reaction mixture were 26.4 cm2, 34.9 cm2 and 216 
43.3 cm2. 217 
Reaction mixtures were sampled periodically up to 312 hours and analyzed 218 
by HPLC and/or UV-Vis Spectroscopy. The oil solutions were submitted to drug 219 
extraction prior HPLC analyses, according to section 2.4 and BHT 2.5 mg/mL was 220 
added to the DMSO during extraction to quench any possible further oxidation reaction 221 
until analysis. All samples were stored at 4 °C, when not analyzed immediately to 222 
quench further reactions from happening. Reaction mixtures are described as Table S1 223 
from Supplementary material.   224 
 225 
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3. RESULTS AND DISCUSSION   226 
3.1 Method validation 227 
AmB 13.0 nM solution in methanol:DMSO (3:2, v/v) was analyzed 6 times for 228 
the suitability study. Figure 2 shows chromatograms of the sample and the blank. AmB 229 
peak area, peak height and retention time from the 6 replicates of AmB 13.0 nM 230 
solution are described in Table 1. AmB peak was well-resolved from elution time of 231 
non-retained components.  232 
TABLE 1 233 
The number of theoretical plates was calculated using six replicates based on 234 
the Equation (1), where tr is the retention time (16.2 min) and W is the peak width. 235 
The calculated number of theoretical plates was 5184, which is superior to 2000, 236 
minimum recommended according to the system suitability test limits [13]. 237 
𝑁 = 16 ቀ௧ೝ
ௐ
ቁ
ଶ
    (1) 238 
The linear regression showed good linearity in a range from 3.2 to 52.0 nM, 239 
providing a correlation coefficient of 0.996 ± 0.003. Additionally, the slope value was 240 
216.36 ± 5.15 and the intercept was 639.92 ± 96.41. Figure 3 shows the calibration 241 
plot used for linearity assessment.  242 
The precision is the amount of scatter in the results obtained from multiple 243 
analyses of a sample. The samples showed low coefficient of variation percentage on 244 
the within-day precision evaluation, which means the method has adequate precision 245 
in analyses performed in the same day with the sample concentration range (from 3.2 246 
to 52.0 nM) (Table 2). Regarding the between-day precision it was possible to observe 247 
that the lower concentration (3.2 nM) had the higher % CV of all three samples; 248 
However, this is expected since inter–day variations on the HPLC system, such as flow 249 
or small temperature changes could have an effect on analyses of very low 250 
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concentrated samples. All % CV in the within- and between-day precision in this study 251 
were ≤ 13 %, which meet the FDA [10] requirement of coefficient of variance ≤ 15% 252 
in order to consider a method precise. However, in research studies it is also usual to 253 
determine acceptances criteria that meet the analytical purposes of the method based 254 
on multiple research studies, especially when developing a method to detect very low 255 
concentrations [14, 15]. Since all samples had acceptable coefficients of variance, it 256 
can be inferred that the method’s precision was considered satisfactory, presenting low 257 
random errors.  258 
The accuracy is the closeness of the measured value to the true value 259 
(recovery). The recoveries of AmB samples at concentrations of 3.2 nM, 13.0 nM and 260 
52.0 nM were 72.75, 87.57 and 101.86 %, respectively (Table 2). Based on FDA 261 
acceptance criteria for recovery (15 % variation from the real concentration), only the 262 
13.0 nM and 52.0 nM samples recovery (87.57 and 101.86%) meet the criteria since 263 
they are with 15 % variation from 100 %. The lower concentration sample (3.2 nM) 264 
had a low recovery rate, showing low accuracy of the method for concentrations as 265 
low as 3 nM.  266 
 267 
TABLE 2 268 
 269 
The limit of detection represents the lowest concentration of AmB capable of 270 
producing a distinguishable response from the noise, typically, three times the noise 271 
level. The LOD was calculated based on ratio of standard deviation of the response 272 
(SD) and the slope estimated from the calibration curve of the standards multiplied by 273 
3 (Eq. (2)). The LOQ was calculated based on the same approach; However, the ratio 274 
was multiplied by 10 for this parameter (Eq. (3)).  275 
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𝐿𝑂𝐷 = ௌ஽×ଷ
ௌ௟௢௣௘
     (2)                                𝐿𝑂𝑄 =  ௌ஽ ×ଵ଴
ௌ௟௢௣௘
    (3) 276 
The calculated LOD was 1.33 nM. The limit of quantification is the lowest 277 
concentration of the drug that can be accurately and precisely quantified; this value 278 
usually corroborates accuracy values for lower concentrations. The calculated LOQ in 279 
this validation was 4.45 nM. LOQ was calculated using SD of the intercept of 280 
calibration curves (three repetitions) and since low concentration samples showed high 281 
% CV in the precision analyses, these samples increased the intercept’s SD, increasing 282 
LOQ. Although the method presented itself as linear from 3.2 to 52.0 nM based on 283 
average values, it is appropriate to work with solutions in the concentration range from 284 
4.45 to 52.0 nM, once the LOQ represents the lowest amounts that can be precisely 285 
quantified. This result is also corroborated by the low recovery percent (accuracy) of 286 
the 3.2 nM AmB solution, indicating that samples with concentrations in this proximity 287 
will not be accurately quantified. In summary, the validation parameters analyzed in 288 
this project show that the method is adequate for detecting low concentrations of AmB 289 
(from 4.45 to 52.0 nM).  290 
3.2 AmB extraction and determination of solubility of AmB in medium-chain 291 
triglyceride:  292 
The yield of extraction was calculated according to Equation (4), where: AmBOil is the 293 
peak area of AmB from solution in oil after extraction and AmBDMSO is the peak area 294 
of the control solution in DMSO. 295 
𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑦𝑖𝑒𝑙𝑑 = ஺௠஻ೀ೔೗ ×ଵ଴଴
஺௠஻ವಾೄೀ
   (4) 296 
The separation process using DMSO was successfully able to extract 297 
amphotericin B from Miglyol® 812 allowing drug from solutions in oil to be analyzed 298 
by HPLC. Based on calculation, relative extraction yield was approximately 81.0 %. 299 
All analytical concentration values of extracted samples in this study are represented 300 
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as corrected values in respect to the dilutions and the yield of the extraction process, 301 
representing true sample concentration. 302 
Extraction results for 0, 1, 2, 4, 8, 30 and 54 hours were approximately 81.3, 303 
82.0, 79.3, 82.7, 80.2, 79.5, 81.8 %.  Analysis of variance (ANOVA) showed no 304 
significant difference of these values at the p < 0.05 level for AmB oil solution samples 305 
extracted at all times. This result is relevant to future stability studies of amphotericin 306 
B in oil since is possible to note that once the drug is kept away from stress conditions, 307 
the extraction process may be conducted up to 50 h after experimental protocol 308 
involving the drug solution without any significant concentration change.  309 
The HPLC method was used to analyze AmB oil solutions in order to 310 
determine the solubility of the drug in medium-chain triglyceride (Miglyol® 812). The 311 
samples contained a surplus of AmB and only the soluble content was analyzed 312 
periodically. Concentration values calculated based on the linear equation were found 313 
to be 1.03 ± 0.01 µM and 1.01 ± 0.02 µM for the duplicate. Regarding AmB in 314 
medium-chain triglyceride, the approximate AmB concentrations used for this study 315 
were < 1.0 µM. 316 
3.3 Determination of AmB degradation pathway 317 
3.3.1 Effect of adsorption on AmB loss of substrate  318 
Adsorption can be chemically defined as the increase of density of fluids in the 319 
vicinities of interfaces or the change in concentration of a substance at the interface as 320 
compared with the neighboring phases [16]. This phenomenon has been described as 321 
responsible for the loss of substrate of different drugs due to adsorption to the surface 322 
of the solution´s container. Reports have been made regarding drugs, such as the 323 
anthracycline antibiotics, to strongly adsorb to medical devices during treatment [17, 324 
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18]. However, to this date it was still unclear if adsorption played a role on the loss of 325 
substrate of AmB in oil.   326 
Figure 4 shows a plot of AmB concentration versus time, where reaction 327 
mixtures of AmB in Miglyol® 812 were stored in glass vials and exposed to different 328 
surface areas by adding different amounts of glass beads. Adsorption experiments in 329 
glass, other than other materials, are important once marketable formulations, such as 330 
Fungizone are stored in glass vials and degradation experiments are performed using 331 
several laboratory glassware.  332 
FIGURE 4  333 
 334 
At 60 °C, AmB appeared to degrade at the same rate regardless of the glass 335 
surface area, suggesting that this drug does not adsorb to this type of container material 336 
at given storage conditions, once it would be expected to find a difference at the 337 
remaining amount of AmB overtime according to the surface area if adsorption played 338 
a relevant role on the loss this drug. Differently, Mizutani and Mizutani (1977) 339 
observed the adsorption of several other drugs to glass surfaces using controlled pore 340 
glass as reference. Reports on the adsorption of epinephrine, atropine, physostigmine, 341 
insulin, and other drugs have been made [19]. 342 
3.3.2 Determination of aggregation state of AmB in reaction mixtures  343 
In order to determine the aggregation state of AmB in methanol and Miglyol® 344 
812, full-wavelength scan spectra were obtained from UV-Vis spectroscopy. This 345 
determination followed the understanding that the aggregation state of this drug can 346 
influence degradation rates and perhaps degradation pathways, as demonstrated by 347 
Lamy-Freund and collaborators [8], which studied the effect of different AmB 348 
aggregation forms on autoxidation in water:DMSO mixture.  Monomeric and 349 
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aggregated AmB UV-Vis scans are widely known and stablished by the literature [7, 350 
8, 20]. AmB in its monomeric form shows four characteristics peaks with maximum 351 
absorbance at around 406-409 nm, whereas the aggregated AmB shows maximum 352 
absorbance at around 327 nm [20].  353 
As observed for different organic solvents (Figure 5), AmB at 0.8 µg/mL can 354 
appear in different aggregation forms. AmB in methanol shows characteristic 355 
monomeric behavior, whereas AmB in chloroform appears to be in its aggregated 356 
form. AmB scan in Miglyol® 812 obtained from UV-Vis spectroscopy does not 357 
provide sustainable information to assure its aggregation state. Thus, for the purposes 358 
of further investigation, methanol was used as main solvent for investigations 359 
involving aggregation, once this organic solvent allows the identification of AmB 360 
aggregation state in UV-Vis spectroscopy.  361 
FIGURE 5 362 
 363 
3.3.3 Effect of radical initiator on AmB degradation 364 
Autoxidation is known to happen in three stages: initiation, propagation and 365 
termination. It happens autocatalytically through free-radical intermediates. Molecular 366 
oxygen in its triplet state (ground state) is involved. The direct reaction between triplet 367 
state oxygen and unsaturated substrates is spin forbidden, once those compounds are 368 
mostly in singlet state. In order for autoxidation to happen, the spin barrier needs to be 369 
overcome by initiating mechanisms, such as the presence activated oxygen species or 370 
free radicals [21].  371 
Based on AmB chemical moieties, oxidation of the polyene group and 372 
formation of epoxides is a likely degradation pathway depending upon the media and 373 
storage conditions. AmB had been proved to autoxidize in different solvents [6]. 374 
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However, is was still unclear if this pathway is responsible for AmB loss in oil. The 375 
use of radical initiators to induce autoxidation at faster rates is a method of great 376 
relevance in the investigations of drug degradation pathways [22].  As suggested by 377 
the literature, AIBN can be used as a radical initiator in stress studies in temperatures 378 
starting at 40 °C [22]. Figure 6 shows a concentration time profile of AmB 0.8 µg/mL 379 
in Miglyol® 812. However, no significant change was observed between the drug 380 
decay of the reaction mixtures with and without the radical initiator. This might 381 
indicate that drug impurities already generate enough radicals to saturate AmB, and 382 
the excess of free radicals generated by AIBN have no influence on increasing 383 
degradation process. 384 
 385 
FIGURE 6 386 
 387 
Since other literature sources mention that temperatures higher than 40 °C 388 
should be used for complete decomposition of AIBN and radical formation, [23] 389 
different temperatures were tested (Figure 7).  390 
 391 
FIGURE 7 392 
 393 
Additionally, carbamazepine was used as a control drug in the oxidation by 394 
radical initiator experiment. This drug has its degradation scheme by oxidation known 395 
and reported in the literature [12]. Figure 8 shows that the addition of AIBN to a 396 
reaction mixture containing carbamazepine in Miglyol® 812 changed the degradation 397 
rate of this drug at 50°C, proving the effectiveness of this radical initiator in this oil. It 398 
is possible to observe that after 24h, carbamazepine concentration in the presence of 399 
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AIBN decayed 50% from the initial concentration (1.0 µg/mL), whereas in the the 400 
sample without AIBN, carbamazepine concentration remained almost unchanged over 401 
the course of 24h at 50°C, showing that AIBN is indeed effective at this given 402 
temperature in Miglyol® 812 to induce drug oxidation. From this experiment, it can be 403 
confirmed that AmB in Miglyol® 812 was not considerably susceptible to oxidation 404 
by radical initiator addition at low and mild temperatures (Figure 7). However, even 405 
without the use of AIBN, AmB degraded in oil, suggesting that the autocatalyzed 406 
oxidation in oil happened. This hypothesis was further explored in the following 407 
section by adding antioxidants to the reaction mixtures.  408 
 409 
FIGURE 8 410 
 411 
3.3.4 Effect of antioxidants on AmB degradation in Miglyol® 812 412 
As described extensively by the literature, antioxidants can be classified based 413 
on how they are capable of stopping or preventing oxidation reactions and may be used 414 
to help understand the oxidation mechanism taking place in reaction mixtures. 415 
Antioxidants can act in different ways, such as quenching reactive oxygen, transferring 416 
electron, transferring hydrogen and chelating metals [24]. Figure 9 shows the 417 
concentration time profile of AmB in reaction mixture with different antioxidants. It 418 
was possible to observe that all studied antioxidants were capable of reducing the 419 
degradation of this drug, confirming that autoxidation is one of the degradation 420 
pathways of AmB in oil based on the mechanisms of the antioxidants.  421 
 422 
FIGURE 9 423 
 424 
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 After 72h, α-tocopherol was able to increase the remaining concentration of 425 
AmB in the reaction mixture from 16% to 48%. This molecule is considered a radical 426 
scavenger and acts a chain-breaking antioxidant. Each tocopherol molecule donates a 427 
hydrogen, generating a new non-radical and a tocopherol-derived radical, which reacts 428 
with another radical from the medium. Thus, each tocopherol molecule is able to 429 
eliminate two free-radicals [25]. It is noteworthy that its activity is temperature 430 
dependent. Its action is limited and non-existent above 100 and 150 °C, respectively 431 
[26]. By its effectiveness, it is possible to infer that in Miglyol, AmB or its impurities 432 
generate free radicals, undergoing autoxidation. 433 
 BHT and propyl gallate are both synthetic phenolic antioxidants. And similar 434 
to α-tocopherol, they donate hydrogen atoms, converting a radical to a non-radical and 435 
converting themselves in radicals that will react with other radicals to make stable 436 
compounds [27]. Although both antioxidants were effective at given concentrations, 437 
temperatures and reaction mixtures, propyl gallate was able to reduce the degradation 438 
of AmB greatly. The effectiveness of phenolic antioxidants may depend upon 439 
activation energy, rate constants, oxidation-reduction potential, volatility, heat 440 
susceptibility and solubility in the media, as well as the composition of the media [26]. 441 
Thus, proper choice of antioxidants for different media and conditions should take in 442 
account their mechanisms, but their effectiveness may vary greatly and should be 443 
determined experimentally. Further data on how these antioxidants effected AmB 444 
degradation in other oils are shown in Supplementary material.  445 
3.3.5 Effect of antioxidant concentration 446 
Concentration and solubility should be taken in consideration when choosing 447 
an antioxidant either for formulation or for degradation studies, as mentioned in the 448 
previous section. Based on solubility properties, BHT was chosen for further studies 449 
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in methanol. Figure 10 shows a concentration time profile of AmB 0.8 µg/mL in 450 
methanol with different BHT concentrations.  451 
 452 
FIGURE 10 453 
 454 
It was possible to observe that BHT concentration did not affect considerably 455 
the loss of AmB in the studied conditions, showing that the amount of substract (BHT) 456 
needed for antioxidation did not affect the loss of AmB on the studied concentrations 457 
of BHT. Based on the assumption that most radicals were eliminated by hydrogen 458 
donation and covalent reaction with generated BHT-radicals and also that autoxidation 459 
depending upon peroxide radicals was fully terminated, we might consider that BHT 460 
did not stopped all AmB loss due to inherent lack of effectiveness of BHT on 461 
preventing autoxidation at given condition or that AmB is undergoing other 462 
degradation processes during autoxidation that also lead to loss of chromophore signal 463 
(reaction on the polyene). 464 
 465 
3.3.6 Effect of different solvents on AmB Degradation 466 
Media effect on chemical reactivity that leads to drug degradation can be 467 
approached according to different parameters, such as intermolecular forces, chemical 468 
interactions and solvent polarity [28]. Those parameters could be properly used when 469 
comparing aqueous media or organic solvents with known chemical properties. 470 
Regarding oils (non-pure solvents), their variable chemical composition makes it 471 
difficult for standardization of those parameters on the literature. Thus, the effect of 472 
different oils on a solute degradation may be better explained in terms of oil chemical 473 
composition. Considering that autoxidation happened in the studied conditions, as 474 
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discussed in the effect of antioxidants on AmB loss, the reaction happened at different 475 
rates in different solvents (Figure 11). 476 
 477 
FIGURE 11 478 
 479 
An increase in AmB loss was observed in Soybean oil when compared to 480 
peanut oil. Although both oils are mainly composed of unsaturated fatty acids, soybean 481 
oil has a higher percentage of these compounds [29, 30]. Thus, making the media more 482 
susceptible to free radical generation under elevated temperatures. As observed in 483 
Figure 11, at 72h of storage at 50 °C protected from light, AmB appeared to be lost 484 
greatly in Miglyol ® 812, compared to Soybean oil and Peanut oil. Miglyol ® 812 is a 485 
mixture of medium-chain triglycerides (mainly caprylic/capric acids), making this oil 486 
less susceptible to be oxidized by free radicals. Different from the other oils, all 487 
radicals generated by AmB and/or its impurities (around 20% according to the 488 
fabricant) are likely to be consumed by AmB molecule itself, due to better oil stability, 489 
increasing AmB loss, whereas for the other oils, unsaturated molecules can also be 490 
oxidized by the consumption of free radicals.  491 
AmB was more stable in methanol at the studied conditions (Figure 11). That 492 
might be related to the chemistry principles of the autoxidation reaction and oxygen 493 
reactivity. Autoxidation is determined by triplet oxygen (ground state/ unpaired spin) 494 
being homolytically broken and converted to free radical or acting as a biradical [24]. 495 
Computational mechanistic studies by Shayan and Vahedpour (2012) have shown that 496 
methanol reactivity with singlet state oxygen (responsible for other oxidation 497 
processes, such as, light catalyzed, see topic 3.3.10) is higher and generates more stable 498 
products than reaction with triplet state oxygen [31]. Therefore, smaller reactivity of 499 
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triplet oxygen (the most found in oxygen molecules) with methanol in autoxidation 500 
conditions reduces AmB degradation. 501 
 502 
3.3.7 Effect of oxidation on the aggregation state of AmB 503 
UV-Vis spectroscopic studies were conducted in methanol in order to 504 
determine if AmB aggregation state changes overtime during oxidation. AmB 0.8 505 
µg/mL and AIBN in methanol were stored at 50°C and periodically analyzed. Figure 506 
12 shows that AmB absorbance decreased overtime and no aggregation state changes 507 
were observed by UV-Vis spectroscopy. The apparent peak increase at 350 nm was 508 
not due to aggregation change, but to the absorbance of AIBN, as shown in the same 509 
figure. 510 
 511 
FIGURE 12 512 
 513 
In addition, when a blank was run with AIBN (Figure 13.B), a non-typical scan 514 
presented itself (regarding aggregation state standard scans); However, in order to 515 
observe if aggregation species were present, DMSO was added to convert all possible 516 
aggregates to monomers and no spectrum change was observed, besides intensity due 517 
to the dilution, showing that the loss of AmB overtime in methanol does not happen 518 
due to change in aggregation state. To prove DMSO effectiveness in converting 519 
aggregational species, an AmB solution in water (18.5 µg/mL) was done and analyzed 520 
(Figure 13.A), where AmB presented itself as aggregated and a second solution of the 521 
same concentration containing DMSO was done (Figure 13.A) and AmB was 522 
converted to monomers due to DMSO presence in the solution.  523 
 524 
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FIGURE 13 525 
 526 
3.3.8 Generation of degradation products by oxidation  527 
Oil samples went through extraction in order to have their AmB content 528 
quantified by HPLC during previous studies. It is possible that detectable degradants 529 
were not extracted by the method developed for AmB. In order to simulate degradation 530 
generation by autoxidation without the influence of the extraction, a reaction mixture 531 
of AmB (160 µg/mL) and AIBN 0.7 mg/mL in methanol was analyzed by HPLC 532 
(Figure 14). AmB concentration was higher than the previous mentioned in this study 533 
in order to provide more substrate to generate higher amounts of degradants. Methanol 534 
was used instead of oil since by using that solvent no extraction step is needed. 535 
 536 
FIGURE 14 537 
 538 
 We did not detect any new peaks being formed while AmB concentration 539 
decreased overtime in the presence of AIBN at 406nm. Additionally, the sample was 540 
analyzed in a wide range of wavelengths to investigate the formation of degradants 541 
with absorbance at different wavelength, and no new peaks were observed. By this 542 
result we can infer that the chromophore (polyene) was modified during degradation 543 
since there is no new peak being detected at 406 nm. It is possible that after oxidation, 544 
the heptaene chain of AmB formed a pentaene epoxide or different structures, based 545 
on the changes displayed by pentaene macrolides after oxidation [32].  546 
3.3.9 Effect of temperature on the oxidation of AmB  547 
Temperature usually affect chemical reactions because at higher temperatures 548 
a larger fraction of molecules possesses more energy than energetic reaction barriers. 549 
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Figure 15 shows the concentration time profile of AmB 0.8 µg/mL in Miglyol ® 812 550 
at a range of temperature from 30 to 80 °C. Typically, reaction rates of drug 551 
degradation follows Arrhenius kinetics, which is a linear dependence of the natural log 552 
of the reaction rate versus the reciprocal of the absolute temperature [28]. Although 553 
AmB degradation increase with the temperature [33], In Figure 18 it is possible to 554 
observe overlap on the concentration of AmB overtime within different temperatures, 555 
showing clearly that there is no linear dependence on the loss of AmB regarding 556 
temperature change. The same behavior was observed for AmB in methanol (See 557 
Figures S1, S2, S3 and S4 from supplementary material). 558 
FIGURE 15 559 
 560 
Non-linear Arrhenius kinetics may be attributed to different parameters, such 561 
as pH shift or complex multistep degradation pathways. Additionally, peroxides, the 562 
primary intermediates in autoxidation propagation reactions are unstable at high 563 
temperatures and more stable at mild temperatures; moreover oxygen solubility 564 
decreases with increasing temperature [34].  565 
 566 
3.3.10 Effect of light on the oxidation of AmB 567 
Oxidation catalyzed by light is another oxidation reaction that might be 568 
responsible for AmB degradation. All studies until now were done under protection of 569 
light once this parameter can initiate oxidation reactions differently. Figure 16 shows 570 
the UV spectra of AmB in methanol under no thermal stress (25 °C) in two distinct 571 
environments, one protected from light and other exposed to light (UV and visible rays 572 
simultaneously, of 8 W/m² and 16800 lx of potency, respectively). As previously 573 
demonstrated, AmB was fairly stable over the course of 72h in methanol at low 574 
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temperatures in the absence of any oxidation initiator (Figure 16.A). On the contrary, 575 
when exposed to light, AmB started to degrade immediately and after 72h of light 576 
exposure almost all AmB degraded.   577 
 578 
FIGURE 16 579 
 580 
 Light catalyzed oxidation, or photosensitized oxidation is not autocatalytic as 581 
autoxidation. This process is dominated by singlet oxygen, which are highly oxidizing 582 
species that can directly react with organic species (spin allowed reactions). However, 583 
triplet oxygen from the environment (mostly responsible for temperature dependent 584 
degradation processes and autoxidation) must be converted to singlet oxygen in the 585 
presence of light [21].   586 
 Light catalyzed oxidation cannot be inhibited by chain-breaking antioxidants 587 
(BHT, propyl gallate and others), but by singlet oxygen quenchers (such as β-588 
carotene). The rate of photosensitized oxidation is usually faster than that of 589 
autoxidation, once singlet state substrates react much faster with singlet oxygen than 590 
with triplet oxygen [21].  591 
 592 
4. CONCLUSIONS 593 
In this study, the method described proved to be reproducible and accurate with 594 
linearity (R2 = 0.996) from 3.2 to 52.0 nM using a UV detector. AmB was successfully 595 
extracted from medium-chain triglyceride based oil prior HPLC analysis. The 596 
degradation pathway of AmB in oil was investigated. Adsorption did not appear to 597 
play a role in AmB degradation in oil. Based on our results, the aggregation state of 598 
AmB in oil is still unclear, thus it was not possible to infer if different aggregation 599 
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forms change the degradation pathway of this drug. The solvents played a role on AmB 600 
degradation, where in methanol the drug appeared to be lost in a typical autoxidation 601 
process, whereas in medium-chain  triglyceride the initiation of the autoxidation to 602 
happen fast, thus, not being detected in the performed experiments. The degradation 603 
pathways were proven to be related to oxidation processes and were found to be light-604 
dependent and further investigations will be conducted in order to assess the kinetics 605 
of the process. Under dark conditions, the most likely pathway for AmB degradation 606 
was autoxidation. Whereas under light exposure, the most likely degradation pathway 607 
was light catalyzed oxidation.  608 
 609 
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Tables 718 
Table 1 – Average values of system suitability parameters with standard 719 
deviation and coefficient of variance percent 720 
Sample AmB 13.0 nM 
 Retention time (min) Peak area Peak Height 
Average (n=6) 16.20 2669.50 110.50 
S.D. 0.02 189.46 4.54 
%CV 0.13 7.09 4.11 
Notes: S.D.: Standard deviation; %CV: Coefficient of variance percent 721 
 722 
 723 
 724 
 725 
 726 
 727 
 728 
 729 
 730 
 731 
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Table 2 – Peak area averages with standard deviation and coefficient of 732 
variance percent obtained from between- and within-day precision 733 
and recovery % from accuracy analyses of amphotericin B standard 734 
solutions 735 
AmB 
Concentration 
(nM) 
Between-day precision 
(n=4) 
Within-day precision 
(n=3) 
Accuracy  
(n=6) 
PA S.D. % CV PA S.D. % CV Recovery % 
3.2 655.83 81.12 12.37 674.66 10.50 1.55 72.75 
13.0 2768.25 172.39 6.23 3151.67 198.65 6.23 87.57 
52.0 11279.67 276.43 2.45 11869.33 96.20 0.81 101.86 
PA: Average peak area; S.D.: Standard Deviation; % CV: Coefficient of variance.  736 
 737 
 738 
 739 
 740 
 741 
 742 
 743 
 744 
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Figures 745 
 746 
 747 
Figure 1 – Structure of amphotericin B showing the numbering of carbon 748 
atoms in the molecule. 749 
 750 
 751 
 752 
 753 
 754 
 755 
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 756 
Figure 2 – Chromatograms obtained by isocratic elution using HPLC. A: blank 757 
(methanol:DMSO (3:2, v/v)); B: AmB 13.0 nM standard solution 758 
in methanol:DMSO (3:2, v/v). 759 
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 770 
Figure 3 – Calibration curve of amphotericin B standard solutions in 771 
methanol:DMSO (3:2) (n=3).  772 
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 782 
Figure 4 – AmB loss versus time plot. AmB concentration of 0.8 µg/mL in 783 
Miglyol® 812. Different surface areas were obtained by adding 784 
glass beads to the vial. 26.4 cm² (no beads), 34.9 cm² (30 glass 785 
beads), 43.3 cm² (60 glass beads).   786 
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 797 
Figure 5 – Scan spectra of AmB 0.8 µg/mL in different organic solvents. 798 
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 813 
Figure 6 – AmB loss versus time plot. AmB concentration of 0.8 µg/mL in 814 
Miglyol® 812 at 40°C, with and without AIBN 0.7 mg/mL. 815 
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 830 
Figure 7 – AmB loss versus time plot. Reaction mixture of AmB0.8 µg/mL in 831 
Miglyol® 812 at different temperatures, with and without AIBN 832 
0.7 mg/mL. 833 
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 841 
Figure 8 –Carbamazepine loss versus time plot. Reaction mixture of 842 
Carbamazepine 1.0 µg/mL in Miglyol® 812 at 50°C, with and 843 
without AIBN 0.7 mg/mL. 844 
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 851 
Figure 9 – AmB 0.8 µg/mL in Miglyol® 812 at 50°C (Control). Other samples 852 
were added of different antioxidants (BHT 2.5 mg/mL, α-853 
tocopherol 1 mg/mL and propyl gallate 5mg/mL).  854 
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 866 
Figure 10 – AmB 0.8 µg/mL in methanol at 50°C added of different 867 
concentrations of BHT (10, 25, 50, 100 and 150 mg/mL).  868 
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 875 
Figure 11 – AmB loss versus time plot. AmB concentration of 0.8 µg/mL in 876 
different solvents at 50 °C. Miglyol® 812, Soybean oil and Peanut 877 
oils were used for comparison among oils and methanol was used 878 
as reference organic solvent.  879 
 880 
 881 
 882 
 883 
 884 
 885 
 886 
 887 
 888 
 889 
 890 
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70 80
A
m
B
 r
em
ai
ni
ng
 [%
]
Time (h)
Peanut oil
Methanol
Miglyol 812
Soybean oil
 
 
 
   
71
 891 
Figure 12 – Wavelength scan spectra of AmB 0.8 µg/mL in methanol stressed 892 
with AIBN 0.7 mg/mL at 50°C for over 72h. Wavelength scan 893 
(280 to 400 nm) of AIBN in methanol.   894 
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 908 
Figure 13 – Wavelength scan spectra of AmB. (A) Blue: AmB 18.5 µg/mL in 909 
water (aggregated state), Red: AmB in water 18.5 µg/mL:DMSO 910 
(3:2, v/v)  (monomeric state). (B) Red:  AmB 0.8 µg/mL and AIBN 911 
0.7 mg/mL in methanol stressed at 50 °C for 4h. Blue: AmB 0.8 912 
µg/mL and AIBN 0.7 mg/mL in methanol stressed at 50 °C for 4h 913 
diluted in DMSO (methanol:DMSO (3:2, v/v)) in order to observe 914 
if the sample aggregates after oxidized. 915 
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 923 
Figure 14 – Chromatogram of reaction mixture containing 160.0 µg/mL AmB 924 
and AIBN 0.7 mg/mL in methanol stressed at 50 °C at starting of 925 
reaction (0h) and after 24 hours.   926 
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 939 
Figure 15 – The concentration time profiles of AmB (0.8 µg/mL) in Miglyol® 940 
812 stressed at 30, 40, 50, 60, 70 and 80 °C for 72 hours.  941 
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 947 
Figure 16 – Full- wavelength scan spectra of AmB 0.8 µg/mL from 0 to 72 h 948 
at 25 °C. A: sample protected from light. B: sample exposed to 949 
light (UV and visible rays simultaneously, of 8 W/m² and 16800 950 
lx of potency, respectively). 951 
 952 
 953 
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SUPPLEMENTARY MATERIAL 954 
Tables 955 
 956 
Table S1 – Reaction mixtures used for different amphotericin B degradation pathway investigations 957 
Substrate 
Solvent Temperature 
Co-solute Pathway test 
Drug Concentration Type Concentration 
Amphotericin B 0.8 µg/mL Miglyol® 812 60 °C - - Adsorption 
Amphotericin B 0.8 µg/mL Miglyol® 812 AT - - Aggregation 
Amphotericin B 0.8 µg/mL Methanol AT - - Aggregation 
Amphotericin B 0.8 µg/mL Methanol 50 °C AIBN 0.7 mg/mL 
Aggregation under 
oxidation condition 
Amphotericin B 0.8 µg/mL Butanol AT - - Aggregation 
Amphotericin B 0.8 µg/mL Octanol AT - - Aggregation 
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Amphotericin B 0.8 µg/mL 
Benzylic 
alcohol 
AT - - Aggregation 
Amphotericin B 0.8 µg/mL Chloroform AT - - Aggregation 
Amphotericin B 0.8 µg/mL Miglyol® 812 30 – 80 °C - - Temperature effect 
Amphotericin B 0.8 µg/mL Methanol 30 – 50 °C - - Temperature effect 
Amphotericin B 0.8 µg/mL Miglyol® 812 50 °C AIBN 0.7 mg/mL Effect of radical initiator 
Amphotericin B 0.8 µg/mL Miglyol® 812 50 °C BHT 2.5 mg/ mL Effect of antioxidant 
Amphotericin B 0.8 µg/mL Miglyol® 812 50 °C propyl gallate 5.0 mg/mL Effect of antioxidant 
Amphotericin B 0.8 µg/mL Miglyol® 812 50 °C α-tocopherol 1.0 mg/mL Effect of antioxidant 
Amphotericin B 0.8 µg/mL Methanol 50 °C AIBN 0.7 mg/mL Effect of radical initiator 
Amphotericin B 0.8 µg/mL Methanol 50 °C propyl gallate 5.0 mg/mL Effect of antioxidant 
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Amphotericin B 0.8 µg/mL Methanol 50 °C  α-tocopherol 1.0 mg/mL Effect of antioxidant 
Amphotericin B 0.8 µg/mL Methanol 50 °C BHT 10.0 mg/mL 
Effect of antioxidant 
concentration 
Amphotericin B 0.8 µg/mL Methanol 50 °C BHT 25.0 mg/ mL 
Effect of antioxidant 
concentration 
Amphotericin B 0.8 µg/mL Methanol 50 °C BHT 50.0 mg/mL 
Effect of antioxidant 
concentration 
Amphotericin B 0.8 µg/mL Methanol 50 °C BHT 100.0 mg/mL 
Effect of antioxidant 
concentration 
Amphotericin B 0.8 µg/mL Methanol 50 °C BHT 150.0 mg/mL 
Effect of antioxidant 
concentration 
Amphotericin B 0.8 µg/mL Soybean oil 50 °C AIBN 0.7 mg/mL Effect of radical initiator 
 
 
    79
Amphotericin B 0.8 µg/mL Soybean oil 50 °C BHT 2.5 mg/ mL Effect of antioxidant 
Amphotericin B 0.8 µg/mL Soybean oil 50 °C propyl gallate 5.0 mg/mL Effect of antioxidant 
Amphotericin B 0.8 µg/mL Soybean oil 50 °C α-tocopherol 1.0 mg/mL Effect of antioxidant 
Amphotericin B 0.8 µg/mL Soybean oil 50 °C - - Effect of antioxidant 
Amphotericin B 0.8 µg/mL Peanut oil 50 °C AIBN 0.7 mg/mL Effect of radical initiator 
Amphotericin B 0.8 µg/mL Peanut oil 50 °C BHT 2.5 mg/ mL Effect of antioxidant 
Amphotericin B 0.8 µg/mL Peanut oil 50 °C propyl gallate 5.0 mg/mL Effect of antioxidant 
Amphotericin B 0.8 µg/mL Peanut oil 50 °C α-tocopherol 1.0 mg/mL Effect of antioxidant 
Amphotericin B 0.8 µg/mL Peanut oil 50 °C - - Effect of antioxidant 
Amphotericin B 160.0 µg/mL Methanol 50 °C - - Degradant generation 
Amphotericin B 160.0 µg/mL Methanol 50 °C AIBN 0.7 mg/mL Degradant generation 
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Carbamazepine 1.0 µg/mL Miglyol® 812 50 °C - - 
Radical initiator 
effectiveness 
Carbamazepine 1.0 µg/mL Miglyol® 812 50 °C AIBN 0.7 mg/mL 
Radical initiator 
effectiveness 
Carbamazepine 1.0 µg/mL Soybean oil 50 °C - - 
Radical initiator 
effectiveness 
Carbamazepine 1.0 µg/mL Soybean oil 50 °C AIBN 0.7 mg/mL 
Radical initiator 
effectiveness 
 958 
 959 
 960 
 961 
 962 
 963 
 964 
 965 
 966 
81 
 
Figures 967 
 968 
Figure S1 – AmB 0.8 µg/mL in Soybean oil at 50°C (Control). Other samples 969 
were added of AIBN 0.7 mg/mL and different antioxidants (BHT 970 
2.5 mg/mL, α-tocopherol 1 mg/mL and propyl gallate 5mg/mL).  971 
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 984 
 985 
Figure S2 – AmB 0.8 µg/mL in Peanut oil at 50°C (Control). Other samples 986 
were added of AIBN 0.7 mg/mL and different antioxidants (BHT 987 
2.5 mg/mL, α-tocopherol 1 mg/mL and propyl gallate 5mg/mL).  988 
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 1001 
Figure S3 – AmB 0.8 µg/mL in methanol at 50°C (Control). Other samples 1002 
were added of AIBN 0.7 mg/mL and different antioxidants (α-1003 
tocopherol 1 mg/mL and propyl gallate 5mg/mL).  1004 
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 1014 
Figure S4 – The concentration time profiles of AmB 0.8 µg/mL AmB in 1015 
methanol stressed at 30, 40 and 50 °C for 264 hours.  1016 
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HIGHLIGHTS 1030 
 1031 
 Amphotericin B in medium chain triglyceride does not adsorb to glass 1032 
surface. 1033 
 Amphotericin B does not change its aggregation state after autoxidation in 1034 
medium chain triglyceride.  1035 
 Amphotericin B undergoes autoxidation in oil. 1036 
 Amphotericin B undergoes light catalyzed oxidation under light exposure. 1037 
 1038 
 1039 
 1040 
 1041 
 1042 
 1043 
 1044 
 1045 
 1046 
 1047 
 1048 
 1049 
 1050 
 1051 
 1052 
 1053 
 1054 
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CHAPTER 3 
 
 
 
This chapter contains a research paper manuscript regarding the degradation 
kinetics of AmB in different oils and in organic solvents. The work features 
degradation scheme based on data and literature evidence, as well as a mathematic 
model for attempting to predict kinetic parameters. The suggested model generated 
empirical data, which were tested against the experimental data to investigate how the 
model fits the experimental results. Such results were showed for different conditions, 
such as temperatures and solvents. 
We intend to submit this research article to the Journal of Pharmaceutical and 
Biomedical Analysis upon completion and editing of this manuscript. 
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ABSTRACT 26 
 27 
The aim of this study is to determine a degradation scheme for amphotericin B 28 
degradation under different environmental conditions, such as light exposure, different 29 
temperatures and solvents, as well as to estimate the kinetic parameters involved based 30 
on an empirical degradation model. For those purposes we recollect experimental data 31 
and findings from the previous work (Part I) for development of schemes and models. 32 
Differential equations were developed to explain AmB loss process. A kinetic model 33 
was successfully used to describe AmB loss in different solvents under dark 34 
environment. Under this condition the loss of AmB involved autoxidation as already 35 
described in previous studies and confirmed by this model. In addition, AmB loss 36 
undergoes a complex degradation pathway, once a simple autocatalytic model could 37 
not describe its loss. In fact, a reversible loss probably related to hydrolysis might be 38 
involved, as demonstrated by the scheme and the kinetic model. A second model 39 
described AmB loss under light exposure successfully. AmB loss in this condition 40 
showed to be pseudo-first order, corroborating literature data on photocatalytic 41 
degradation of pharmaceutical molecules. Due to complex degradation pathway, the 42 
kinetics of the different processes leading to AmB degradation could not be 43 
distinguished.  44 
 45 
Keywords: Amphotericin B; Autoxidation; Photocatalytic oxidation; Drug 46 
Degradation. 47 
 48 
 49 
 50 
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1. INTRODUCTION  51 
 52 
Amphotericin B (AmB) is an antifungal and antiprotozoal drug that was 53 
originally isolated from Streptomyces nodosus. Chemically, this molecule has a 54 
macrocyclic lactone ring composed of 37 carbons, with a heptaene chain from carbon 55 
20 to carbon 33, providing a non-polar characteristic to the molecule [1]. The opposite 56 
side has seven hydroxyl groups and one carboxyl group providing some polarity to 57 
AmB. As a result, this molecule has amphiphilic properties [2]. An amino sugar group 58 
(3-Amino-3,6-dideoxy-β-D-mannopyranose) is connected to the main macrocyclic 59 
ring by an o-glycoside bond. AmB is a zwitterion with amphoteric properties due to 60 
the presence of two ionizable groups, a carboxyl (pKa 5.5) and primary amine (pKa 10) 61 
[3, 4]. Figure 1 shows AmB chemical structure. 62 
 63 
FIGURE 1 64 
 65 
 To overcome drawbacks such as low solubility and toxicity, this drug has been 66 
delivered in lipidic carries opposed to its traditional formulation with deoxycholate 67 
(micellar system) [5]. Although being an old molecule, little is known regarding its 68 
degradation scheme and kinetics in lipid media. Chemical stability, hence, degradation 69 
and kinetic studies are of great relevance when it concerns safety and efficacy of drug 70 
products [6, 7]. When it comes to AmB, its degradation/toxicity relation has not been 71 
fully elucidated, as its toxicity is mostly attributed to its aggregation state. However, 72 
if drug degradation plays a role on toxicity is still a matter to be discussed more widely. 73 
To begin the study of this hypothesis, studies involving AmB behavior in separate 74 
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solvents that compose lipidic complex drug delivery systems are required. Such studies 75 
start with elucidating possible degradation pathways and then investigating 76 
degradation kinetics and degradants structures.  77 
Studies by Lamy-Freund, Ferreira and Schreier demonstrated that AmB 78 
undergoes autoxidation in a mixed media composed of Water/DMSO. This study 79 
investigated only the formation of free radicals opposite from loss of substrate [8]. 80 
Rickards and Smith [9] studied the autoxidation of polyenes of the filipin complex and 81 
lagosin. These molecules are similar in structure to AmB as they are macrocyclic 82 
lactone rings with polyene chains in one of their sides. However, different from AmB, 83 
they contain pentaene chains whether than heptaene. The study found that concentrated 84 
solutions of lagosin, at dark conditions, were susceptible to loss, which was slightly 85 
prevented by the addition of Butylated Hydroxyanisole (BHA). The study also 86 
confirmed conversion from pentaene groups to tetraene after degradation with epoxide 87 
formation [9]. 88 
In a previous study conducted by our group in which AmB was in methanol 89 
and oil solutions, we showed that autoxidation is only one of the possible oxidation 90 
pathways that this drug can undergo, depending upon storage conditions [10]. It was 91 
also discovered that aggregation state does not change along stress testing and that 92 
adsorption does not play a role on AmB loss when soluble in oil. The study showed 93 
that AmB loss was increased in methanol in the presence of a radical initiator (AIBN) 94 
and that in the presence of several antioxidants the loss of AmB decreased in different 95 
oils. Antioxidants responsible for hydrogen donation and radical scavenging were 96 
used. These results confirmed that autoxidation is one of the degradation pathways of 97 
AmB in oil under light protection. However, the degradation of AmB in oil was not 98 
temperature dependent, suggesting that multiple and complex degradation pathways 99 
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could be involved. In the light of this hypothesis, another condition was studied. When 100 
exposed to light, at ambient temperature and no radical initiator, a fast rate degradation 101 
reaction took place. Thus, this drug can also undergo a different oxidation mechanism, 102 
photosensitized or photocatalytic oxidation [10].  103 
This study takes place after the Article titled “Studies on amphotericin B 104 
instability in lipid-based media, Part I: Identification of degradation pathways as 105 
function of mixture conditions”, as it provides further investigation on amphotericin B 106 
instability phenomena in lipid-based media. The aim of this study is to determine a 107 
degradation scheme for AmB degradation under different storage conditions in 108 
different oil reaction mixtures as well as to estimate the kinetic parameters involved 109 
based on an empirical degradation model. For that purpose, we herein recollect 110 
experimental data and findings from the previous work (Part I) for development of 111 
schemes and models. 112 
 113 
2. METHODS 114 
2.1 Determination of degradation scheme and model for substrate loss under 115 
dark and light exposure 116 
A proposed degradation scheme was proposed for AmB loss under dark 117 
conditions, at 0.86 µM in different solvents, stored from 30 to 80 °C. The fraction of 118 
AmB loss under these conditions was calculated according to Equation 1, where 119 
AmB0, AmBt and AmB∞ were initial AmB concentration, AmB concentration at each 120 
given time point and remaining AmB concentration at the end of the degradation plot, 121 
respectively. 122 
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝐴𝑚𝐵 𝑙𝑜𝑠𝑠 = 1 −  ቀ ஺௠஻బ ି ஺௠஻೟
஺௠஻బ ି ஺௠஻ಮ
ቁ (1) 123 
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The plot of AmB loss fraction in Miglyol® 812 and Methanol under the 124 
conditions above versus time are shown in Figures 2 and 3, respectively. 125 
 126 
FIGURE 2 127 
 128 
FIGURE 3 129 
 130 
A proposed scheme was developed, as well as the differential equations for the 131 
loss of AmB under these conditions based on empirical estimation and degradation 132 
profile analysis. An empirical model was developed according to the degradation 133 
profiles mentioned above and previous studies regarding degradation pathways in the 134 
same conditions. Figure 3 shows a loss of AmB consistent with autocatalytic 135 
degradation, consistent with sigmoidal profiles displayed by autoxidation reactions. 136 
This is consistent with the information provided in previous studies in methanol [10]. 137 
On the other hand, the profile displayed in Figure 2 for AmB in Miglyol® 812 does 138 
not show the characteristic sigmoidal shape, instead is more consistent with log-linear 139 
biphasic degradation. Degradation scheme for fitting both types of profiles is shown 140 
and discussed in the results section. 141 
Similarly, the fraction of AmB loss in methanol under light exposure at 25°C 142 
was calculated according to Equation 1. Degradation scheme, differential equation and 143 
degradation model based on empirical estimation were also developed and are 144 
described in the results section. 145 
 146 
 147 
 148 
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2.2 Model parameters estimation method 149 
The Advanced Modeling and Simulation Tool Kit (AMASTK, UI Copyright 150 
2012) was used for nonlinear optimization, simulation and kinetic parameter 151 
estimation. AMASTK was developed by Dr. Stephen Stamatis in R, an open access 152 
programming language and software environment, which was used for data analysis, 153 
calculations and graphical display.  A package for R named deSolve was used to 154 
integrate the ordinary differential equations (ODE) described in the previous sections 155 
according to each condition described [11]. Another package (FME) was necessary to 156 
fit the experimental data to model output concentration as a function of time [12]. 157 
 158 
3. RESULTS AND DISCUSSION 159 
3.1 Model for substrate loss under dark storage  160 
The fraction of AmB versus time profile of AmB in medium chain triglyceride 161 
shown in Figure 2 is not consistent with traditional autoxidation sigmoidal profiles. 162 
However, according to previous studies, it is known that AmB undergo autoxidation 163 
in this solvent at 50°C [10]. On the contrary, degradation profile of AmB in methanol 164 
(Figure 3) is sigmoidal; However, empirical models consistent with only reversible 165 
loss of substrate or autocatalysis did not fit properly the observed data for both 166 
solvents. Thus, these profiles may be representative of a complex degradation scheme 167 
involving multiple pathways, including autoxidation [13]. A proposed scheme 168 
describing the loss of AmB in this condition is shown in Figure 4. 169 
 170 
FIGURE 4 171 
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The proposed scheme involves both autoxidation, where an oxidized fraction 172 
of AmB is also included as substrate (AmBox) and a reversible loss compatible with 173 
possible hydrolytic process due to residual moisture in the oil sample. Hydrolysis 174 
experimental conditions were not previous investigated for oil solutions; However, the 175 
literature reports that oils stored under different humidity levels show different values 176 
of peroxide values and acid index, as those indexes increase with increasing humidity 177 
and they are related to increased chemical instability [14]. Additionally, drug 178 
degradation depend on water activity on the solvent, which might result from different 179 
characteristics of the reactions such as temperature and the solvent itself, besides the 180 
amount of residual water on the medium [15]. 181 
The differential equation that represents the AmB loss is shown in Equation 2. 182 
The initial fraction of AmBox was a fix parameter used to determined kinetic 183 
parameters and UC is used for Unknown Compounds.  184 
ௗ௙஺௠஻
ௗ௧
=  −(𝑘ଵ + 𝑘௢௫) (𝐴𝑚𝐵) (𝐴𝑚𝐵௢௫) + 𝑘ିଵ (𝑈𝐶)  (2) 185 
The proposed differential equation based on the empirical degradation scheme 186 
was fed to the Advanced Modeling and Simulation Tool Kit (AMASTK). Estimated 187 
rate constants are shown in Table 1, values were optimized by fitting observed data to 188 
the model predicted using AMASTK. 189 
 190 
TABLE 1 191 
 192 
AmB loss in Miglyol® 812 from 30 ºC to 80º did not show to be linear, as the 193 
rate constants did not increase proportionally with the temperature (Table 1). Chemical 194 
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processes that do not follow Arrhenius kinetics may be explained by several factors, 195 
such as: phase transitions; change in oxygen solubility in the media over a different 196 
range of temperature; and multi-step reaction pathways, as one of reaction steps of 197 
pathway might depend on a temperature barrier to be overcome, the reactions can 198 
occur differently at different temperature range [16].  199 
Observed data, are in good agreement with the predicted model. Figures 5 and 200 
6 shows that the model was suitable for either degradation profiles of AmB in Miglyol 201 
812 and methanol, suggesting that AmB indeed undergo different pathways in 202 
different solvents and that this model can account for both complex pathway 203 
adequately. 204 
FIGURE 5 205 
 206 
FIGURE 6 207 
 208 
 The model was also applied to determining theoretical fraction values of AmB 209 
overtime for different oils used in the study. The predicted model was in agreement 210 
with the observed data of AmB in Peanut oil (Figure 7). The plot shows data points 211 
that did not fit the predicted model adequately. However, this is probably due to 212 
experimental scatter, once the predicted values line follows the overall degradation 213 
trend of the observed data. Similarly, Figure 8 shows the plot of the predicted values 214 
from the model and observed data of AmB loss in Soybean oil.  215 
 216 
FIGURE 7 217 
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 218 
FIGURE 8 219 
 220 
3.2 Model for substrate loss under light exposure  221 
According to literature, photochemical oxidation follows first order kinetics 222 
[17, 18]. Although having a similar reaction mechanism to autoxidation, the reaction 223 
initiated by light happens at faster rates, thus, showing no characteristic initiation lag 224 
decay, as in the autoxidation processes. The result is a pseudo-first order reaction [17, 225 
18].  226 
Accordingly, Figure 9 is AmB 0.86 µM degradation scheme at 25 °C in 227 
methanol stored under light exposure (Visible and UV-light). The scheme shows a 228 
direct loss of AmB to unknown degradation products under light. 229 
 230 
FIGURE 9 231 
 232 
 The loss of AmB under this condition can be described by the differential 233 
equation 3. 234 
ௗ௙஺௠஻
ௗ௧
= −𝑘௢௫(𝐴𝑚𝐵) (3) 235 
Rate constant estimation showed a kox of 0.076 h-1 that represents the overall 236 
rate of AmB loss at this condition. The model was in good agreement with the observed 237 
data as shown in Figure 10. 238 
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 239 
FIGURE 10 240 
 241 
 Photodegradation of AmB is phenomenon already well established in the 242 
literature [19, 20]; However, its kinetic study and its difference from oxidation 243 
degradation profiles under light protection was not well stablished in the literature. 244 
Previous study showed the difference in degradation pathway between light catalyzed 245 
oxidation and autoxidation [10]. The empirical models developed in this work support 246 
the difference between these processes in non-aqueous solvents, since they showed to 247 
be in agreement with our experimental data.  248 
3.3 AmB degradation products by oxidative pathways  249 
Based on the results obtained from previous study [10] and on the good 250 
agreement of the empirical models with the observed degradation data on this study, 251 
it is well stablished that AmB undergoes oxidation processes. As hypothesized and 252 
showed on the degradation scheme for AmB loss under light protection, a complex 253 
degradation pathway may be involved with its loss; However, autoxidation is one of 254 
the processes that can be confirmed to happen. In addition, under light catalysis, this 255 
drug is also oxidized. 256 
Based on AmB moieties, different chemical groups could be target of chemical 257 
degradation reactions [21]. Based on basic chemistry, the group most likely to be 258 
oxidized first on AmB is the conjugated polyene [22]. Gagós and Czernel [22] induced 259 
AmB oxidation in aqueous media, at different pH and suggested possible degradants 260 
based on fluorescence studies. The study is in agreement with the findings of Rickards 261 
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and collaborators [9], which determined that the polyene macrolides lagosin and filipin 262 
undergo oxidation and that the target group of the reaction is the polyene chain.  263 
 Polyene chain in AmB molecule goes from carbon 20 to carbon 33 [1], where 264 
the central double bonds are less reactive due to resonance. Thus, the double bonds of 265 
the two ends of the polyene chain are more susceptible to oxidation. The prime product 266 
of this oxidation process generates epoxide groups, regardless of the medium, as 267 
shown by Rickards and Collaborators [9]. Nevertheless, if the medium is aqueous or 268 
an organic medium with high humidity levels, the epoxide can hydrolyze and generate 269 
dialcohols, as described for oxidation in aqueous medium by Gagós and Czernel [22].  270 
 Further spectroscopic, chromatographic and drug synthesis studies are required 271 
to accurately isolate, identify and synthetize drug degradation products from AmB 272 
reaction mixtures in different conditions. 273 
4. CONCLUSIONS 274 
An empirical degradation scheme was developed and differential equations 275 
were developed to explain AmB loss process. A kinetic model was used to describe 276 
AmB loss in different solvents under dark environment with success. Under this 277 
condition the loss of AmB involved autoxidation as already described in previous 278 
studies and confirmed by this model. In addition, AmB loss undergoes a complex 279 
degradation kinetics, once a simple autocatalytic model could not describe its loss. In 280 
fact, a reversible loss probably related to hydrolysis might be involved, as 281 
demonstrated by the scheme and the kinetic model. A second model described AmB 282 
loss under light exposure successfully. AmB loss in this condition undergoes a pseudo-283 
first order kinetics, corroborating literature data on photocatalytic degradation of 284 
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pharmaceutical molecules. Due to complex degradation pathway, the kinetics of the 285 
different processes leading to AmB degradation could not be distinguished.  286 
 287 
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Tables  356 
Table 1 – Estimated rate constants for amphotericin B degradation at different 357 
reaction conditions under light exposure (obtained by using 358 
AMASTK®, for estimations and optimization) 359 
Solvent Temperature k1 (h-1) k-1 (h-1) kox (h-1) 
Miglyol® 812a 30 °C 0.130 0.082 0.127 
Miglyol® 812 a 40 °C 0.151 0.102 0.142 
Miglyol® 812 a 50 °C 0.218 0.099 0.139 
Miglyol® 812 a 60 °C 0.154 0.034 0.249 
Miglyol® 812 a 80 °C 0.158 0.007 0.204 
Methanol 50 °C 0.021 0.016 0.204 
Peanut oil 50 °C 0.037 0.015 0.214 
Soybean oil 50°C 0.072 0.010 0.250 
a Medium chain triglyceride marketable mixture of capric and caprylic acids. 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
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Figures 369 
 370 
Figure 1 – Molecular Structure of amphotericin B  371 
 372 
 373 
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 375 
 376 
 377 
 378 
 379 
 380 
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 381 
Figure 2 – Fraction of AmB loss versus time, where initial AmB concentration 382 
was 0.86 µM in Miglyol® 812, stored under dark conditions at 50 383 
°C. 384 
 385 
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 389 
 390 
 391 
 392 
 393 
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 395 
Figure 3 – Fraction of AmB loss versus time, where initial AmB concentration 396 
was 0.86 µM in methanol, stored under dark conditions at 50 °C 397 
 398 
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 404 
 405 
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Figure 4 – Proposed AmB degradation scheme under dark storage 407 
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 419 
Figure 5 – Fraction of AmB loss versus time, where initial AmB concentration 420 
was 0.86 µM in Miglyol® 812, stored under dark conditions at 50 421 
°C, with observed data and predicted model values. 422 
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 432 
Figure 6 – Fraction of AmB loss versus time, where initial AmB concentration 433 
was 0.86 µM in methanol, stored under dark conditions at 50 °C, 434 
with observed data and predicted model values. 435 
 436 
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 441 
 442 
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 444 
Figure 7 – Fraction of AmB loss versus time, where initial AmB concentration 445 
was 0.86 µM in peanut oil, stored under dark conditions at 50 °C, 446 
with observed data and predicted model values. 447 
 448 
 449 
 450 
 451 
 452 
 453 
 454 
 455 
 456 
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 457 
Figure 8 – Fraction of AmB loss versus time, where initial AmB concentration 458 
was 0.86 µM in soybean oil, stored under dark conditions at 50 °C, 459 
with observed data and predicted model values. 460 
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 470 
Figure 9 – Proposed AmB degradation scheme in methanol under light 471 
exposure. 472 
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 483 
Figure 10 – Fraction of AmB loss versus time, where initial AmB 484 
concentration was 0.86 µM in methanol, stored under light 485 
exposure (UV and visible rays simultaneously, of 8 W/m² and 486 
16800 lx of potency, respectively) at 25 °C, with observed data and 487 
predicted model values. 488 
 489 
 490 
 491 
 492 
 493 
 494 
 495 
 496 
 
 
 
   
113
HIGHLIGTHS 497 
 498 
 Amphotericin B degradation undergoes a complex pathway; 499 
 Degradation scheme for amphotericin B loss in oil under dark environment 500 
involves autocatalysis and reversible loss of substrate; 501 
 Amphotericin B loss in methanol under light undergoes a pseudo-first order 502 
kinetics; 503 
 Oxidative degradation product formation from amphotericin B might involve 504 
epoxide formation in the polyene chain; 505 
114 
 
CONCLUSIONS 
 
This thesis initially reviewed background concepts, usage, pharmacology, in-
vitro and in-vivo studies and further information regarding microemulsions containing 
AmB and its freeze-drying as a method for stability improvement. The introduction 
showed the information recollected from the literature regarding nanotechnological 
use of AmB that driven the experimental section of this research, once we had limited 
information on the literature from AmB chemical instability itself and no chemical 
kinetics information to this moment in lipid-based systems.  
From chapter 2, an analytical method in HPLC was successfully developed and 
validated. The method proved to be reproducible and accurate with linearity (R2 = 
0.996) from 3.2 to 52.0 nM using a UV detector. LOD and LOQ were 1.33 and 4.45 
nM, respectively. AmB was successfully extracted from medium-chain triglyceride 
based oil prior HPLC analysis.  
The degradation pathway of AmB in oil was investigated. Adsorption to glass 
surface and aggregation did not appear to play a role in AmB degradation in medium 
chain triglyceride. The degradation pathways were related to oxidation processes, as 
hypothesized initially based on AmB moieties and the media used. Under protection 
from light in different oils, the most likely pathway for AmB degradation was 
autoxidation. The loss of AmB was not temperature dependent, suggesting a complex 
degradation pathway involving not only autoxidation. Whereas under light exposure, 
the most likely degradation pathway was light catalyzed oxidation, as investigated in 
methanol using UV-Vis spectroscopy.    
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In chapter 3, empirical degradation schemes were proposed and differential 
equations were developed to explain AmB loss process. A kinetic model was used to 
describe AmB loss under protection from light in different solvents. The model was in 
good agreement with the observed data and it was based on the biexponential 
reversible loss and autocatalytic loss of AmB. The autocatalytic loss was showed to 
happen in the autoxidation experiments. However, a simple autocatalytic model did 
not describe the data generated. Thus, it was proved by the model that AmB undergoes 
a complex degradation kinetics, as hypothesized initially by the absence of 
temperature-dependence. Additionally, the biexponential kinetic model, suggestive of 
reversible loss, is probably related to hydrolysis due to residual water from the 
solvents.  
A second model described AmB loss under light exposure successfully. AmB 
loss in this condition showed to be pseudo-first order. Constant rates described in the 
model were estimated. However, due to complex degradation pathway, the kinetics of 
the different processes leading to AmB degradation could not be distinguished.  
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APPENDIX 
 
 
 As the main area of expertise of my research laboratory in Brazil and as part of 
the continuous studying on development and nanotechnology, collaborations studies 
are often conducted and I took part on other researches along with developing my 
thesis. 
This section of the Thesis is dedicated to show the publications in scientific 
journals I was involved with as main and/or co-author in the area of nanotechnology 
during the period of time of execution of this PhD research. They were of great 
importance on my intellectual learning and developing as a doctoral student in 
Pharmaceutical Nanotechnology and could not go unnoticed on this document. 
However, they were not the main objective of this Thesis. Thus, they will not be further 
discussed.  
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